HIV

Showing 15 posts of 197 posts found.

Gilead shares phase 3 results from HIV prevention trial

June 21, 2024
Research and Development Gilead, HIV, Infections and infestations, clinical trial

Gilead Sciences has announced results from an interim analysis of its pivotal, phase 3 PURPOSE 1 trial, which assessed the …

Gilead and Merck share data from phase 2 trial of HIV treatment

March 7, 2024
Research and Development Gilead Sciences, HIV, HIV/AIDS, Merck, clinical trials

Gilead Sciences and Merck (known as MSD outside of the US and Canada) have announced results from the phase 2 …

ViiV Healthcare shares interim data from phase 3 trial for injectable HIV treatment

February 21, 2024
Research and Development Cabenuva, HIV, HIV/AIDS, ViiV Healthcare, clinical trial, injectables

ViiV Healthcare has announced results from an interim analysis of the phase 3 LATITUDE trial, which assessed Cabenuva (cabotegravir and …

China’s NMPA approves ViiV Healthcare’s Vocabria in combination with Rekambys for HIV treatment

October 26, 2023
Research and Development HIV, HIV/AIDS, NMPA, ViiV Healthcare, Vocabria

ViiV Healthcare has announced that the National Medical Products Administration (NMPA) of China has approved Vocabria (cabotegravir injection) used in …

Vaccine image

ViiV Healthcare gains positive CHMP opinion for cabotegravir for HIV prevention

July 24, 2023
Medical Communications CHMP, EMA, HIV, HIV/AIDS, ViiV Healthcare, cabotegravir

GSK has announced that ViiV Healthcare has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal …

FDA relaxes blood donation regulations for MSM

May 12, 2023
Medical Communications FDA, HIV, HIV/AIDS, blood donation

The US Food and Drug Administration (FDA) has released updated guidance for blood donation which relaxes the rules for donations …

GSK’s ViiV and Halozyme to collaborate on ‘ultra-long acting’ HIV drugs

June 22, 2021
Manufacturing and Production GSK, HIV, ViiV Healthcare

ViiV Healthcare, the specialist HIV company majority owned by GlaxoSmithKline (GSK), is to collaborate with Halozyme Therapeutics, giving it exclusive …

New HIV prevention drug application submitted to FDA

May 5, 2021
Research and Development FDA, HIV

ViiV Healthcare have initiated a rolling submission of a new drug application (NDA) with the FDA for their long-acting HIV …

gilead-sciences

Gilead and MSD partner to develop and commercialise two-drug HIV regimen

March 16, 2021
Manufacturing and Production Gilead, HIV, MSD

Gilead and MSD, known as Merck in the US and Canada, have entered into an agreement to co-develop and co-commercialise …

landing-hero-images1

ViiV presents positive long-term data for combined HIV treatment

March 8, 2021
Sales and Marketing HIV, ViiV Healthcare

ViiV Healthcare has presented positive long-term data from its global Phase IIIb ATLAS-2M study of the first complete, long-acting regimen …

landing-hero-images1

ViiV’s HIV drug Rukobia gets EC marketing authorisation

February 9, 2021
Manufacturing and Production HIV, ViiV

The European Commission (EC) has authorised ViiV Healthcare’s Rukobia (fostemsavir) 600mg extended-release tablets for use in combination with other antiretroviral …

scripps_research_web_03-18-19_t670

Scripps Research and IAVI report positive findings from HIV vaccine Phase I trial

February 4, 2021
HIV

Scripps Research and IAVI have returned positive Phase I results in their hunt for a HIV vaccine, detecting a targeted …

landing-hero-images1

ViiV’s long-acting HIV drug Cabenuva gets FDA approval

January 22, 2021
Medical Communications HIV, ViiV Healthcare

The FDA has approved ViiV’s Cabenuva, the first and only complete long-acting regimen for the treatment of HIV-1 infection in …

viiv

ViiV and Chelsea & Westminster Hospital launch digital service for HIV patients

January 18, 2021
Sales and Marketing HIV, ViiV Healthcare

Global specialist HIV company ViiV Healthcare and Chelsea and Westminster Hospital NHS Foundation Trust have launched a new service, Klick, …

landing-hero-images1

ViiV gets EU approval for children’s HIV treatment

January 13, 2021
Research and Development EU, HIV, ViiV

ViiV Healthcare, the global specialist HIV company, has received marketing authorisation from the European Commission for Tivicay (dolutegravir) 5mg dispersible …

Latest content